

Giacomo De Luca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4936446/publications.pdf>

Version: 2024-02-01

86
papers

3,643
citations

201674
27
h-index

144013
57
g-index

87
all docs

87
docs citations

87
times ranked

6246
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e325-e331.	3.9	808
2	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. <i>European Journal of Internal Medicine</i> , 2020, 76, 43-49.	2.2	349
3	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1277-1285.	0.9	212
4	GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e465-e473.	3.9	173
5	Ventricular Arrhythmias in Myocarditis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1046-1057.	2.8	148
6	Arrhythmias in myocarditis: State of the art. <i>Heart Rhythm</i> , 2019, 16, 793-801.	0.7	142
7	Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e253-e261.	3.9	140
8	Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 428-436.	3.4	130
9	Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: Potential utility of immunosuppressive therapy in cardiac damage progression. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 526-535.	3.4	119
10	Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 956-964.	1.8	98
11	B cells in systemic sclerosis: A possible target for therapy. <i>Autoimmunity Reviews</i> , 2011, 10, 624-630.	5.8	68
12	Myocarditis: An Interleukin-1-Mediated Disease?. <i>Frontiers in Immunology</i> , 2018, 9, 1335.	4.8	53
13	Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. <i>Microvascular Research</i> , 2021, 133, 104071.	2.5	49
14	Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis: A Prospective Cohort Study Shows ECG Indexes Predicting the Worse Outcome. <i>PLoS ONE</i> , 2016, 11, e0153012.	2.5	48
15	Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study. <i>European Journal of Internal Medicine</i> , 2019, 60, 46-53.	2.2	43
16	Low prevalence of arrhythmias in clinically stable COVID-19 patients. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 891-893.	1.2	43
17	Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. <i>European Journal of Internal Medicine</i> , 2021, 93, 87-94.	2.2	41
18	Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease. <i>Frontiers in Immunology</i> , 2018, 9, 1233.	4.8	37

#	ARTICLE	IF	CITATIONS
19	Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. <i>European Journal of Internal Medicine</i> , 2018, 57, e11-e12.	2.2	36
20	Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 675678.	4.8	35
21	Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis. <i>Rheumatology</i> , 2020, 59, 2523-2533.	1.9	35
22	Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. <i>Annals of Internal Medicine</i> , 2018, 169, 819.	3.9	34
23	The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. <i>Rheumatology</i> , 2021, 60, 5028-5041.	1.9	34
24	Impact of systemic immune-mediated diseases on clinical features and prognosis of patients with biopsy-proved myocarditis. <i>International Journal of Cardiology</i> , 2019, 280, 110-116.	1.7	33
25	Immunosuppressive Therapy and Risk Stratification of Patients With Myocarditis Presenting With Ventricular Arrhythmias. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1221-1234.	3.2	32
26	Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 440-441.	0.9	32
27	Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. <i>Arthritis Research and Therapy</i> , 2019, 21, 54.	3.5	31
28	Therapeutic strategies for virus-negative myocarditis: a comprehensive review. <i>European Journal of Internal Medicine</i> , 2020, 77, 9-17.	2.2	30
29	Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review.. <i>European Journal of Internal Medicine</i> , 2020, 78, 17-25.	2.2	29
30	Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. <i>Frontiers in Pharmacology</i> , 2020, 11, 598308.	3.5	29
31	Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement. <i>Frontiers in Immunology</i> , 2021, 12, 653950.	4.8	26
32	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 24-32.	1.7	25
33	Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 509-514.	3.4	24
34	Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience. <i>Rheumatology</i> , 2020, 59, 171-175.	1.9	23
35	Hybrid FDG-PET/MR or FDG-PET/CT to Detect Disease Activity in Patients With Persisting Arrhythmias After Myocarditis. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 288-292.	5.3	22
36	Life-threatening arrhythmias in a scleroderma patient: the role of myocardial inflammation in arrhythmic outburst. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 78-80.	1.1	21

#	ARTICLE	IF	CITATIONS
37	Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. <i>Rheumatology</i> , 2020, 59, 3731-3736.	1.9	21
38	Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series. <i>Arthritis and Rheumatology</i> , 2022, 74, 1302-1303.	5.6	21
39	Efficacy and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis: A prospective cohort study. <i>Journal of Autoimmunity</i> , 2020, 106, 102330.	6.5	20
40	Tumour-associated antigens in systemic sclerosis patients with interstitial lung disease: association with lung involvement and cancer risk. <i>Rheumatology</i> , 2015, 54, 1991-1999.	1.9	18
41	QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk. <i>International Journal of Cardiology</i> , 2017, 239, 33.	1.7	18
42	Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients. <i>Rheumatology</i> , 2021, 60, 465-467.	1.9	18
43	Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease. <i>Journal of Neurology</i> , 2018, 265, 273-284.	3.6	17
44	The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease. <i>Oncotarget</i> , 2018, 7, e1440929.	4.6	17
45	Telemedicine in myocarditis: Evolution of a multidisciplinary "disease unit" at the time of COVID-19 pandemic. <i>American Heart Journal</i> , 2020, 229, 121-126.	2.7	17
46	The Spectrum of COVID-19-Associated Myocarditis: A Patient-Tailored Multidisciplinary Approach. <i>Journal of Clinical Medicine</i> , 2021, 10, 1974.	2.4	16
47	Clinical Applications of FDG-PET Scan in Arrhythmic Myocarditis. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1771-1780.	5.3	16
48	Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e11-e11.	0.9	15
49	Patient-reported outcome instruments in clinical trials of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 90-102.	1.7	14
50	Drug retention rates of biological agents in adult onset Still's disease. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1-6.	3.4	14
51	Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e143-e146.	0.9	13
52	Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology. <i>Journal of Rheumatology</i> , 2022, 49, 176-185.	2.0	12
53	Anti-Ku syndrome with elevated CK: association with myocardial involvement in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e113-e113.	0.9	10
54	Response to: "More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia" by Ferraccioli. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e158-e158.	0.9	10

#	ARTICLE	IF	CITATIONS
55	Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease. <i>Blood</i> , 2021, 138, 1554-1569.	1.4	10
56	Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation. <i>Rheumatology</i> , 2022, 61, 4409-4419.	1.9	10
57	Large-vessel Vasculitis Affecting the Aorta and its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature. <i>Journal of Rheumatology</i> , 2020, 47, 1780-1784.	2.0	9
58	Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience. <i>Autoimmunity Reviews</i> , 2021, 20, 102981.	5.8	9
59	Troponin in Stable Ischemic Heart Disease and Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 1976-1979.	27.0	8
60	Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance. <i>Journal of Clinical Rheumatology</i> , 2019, Publish Ahead of Print, .	0.9	7
61	Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates. <i>Diagnostics</i> , 2021, 11, 2165.	2.6	7
62	Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases. <i>Clinical Rheumatology</i> , 2022, 41, 2261-2267.	2.2	7
63	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	1.9	7
64	Heart Involvement in Systemic Sclerosis: the Role of Magnetic Resonance Imaging. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 343-357.	6.5	6
65	The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis. <i>Journal of Multidisciplinary Healthcare</i> , 2022, Volume 15, 815-824.	2.7	6
66	Advances in potential targeted therapies for Erdheim-Chester disease. <i>Expert Opinion on Orphan Drugs</i> , 0, , 1-8.	0.8	5
67	The target on B cells in Systemic Sclerosis: a “midsummer dream” to extinguish inflammation and prevent early disease progression to fibrosis. <i>Clinical Rheumatology</i> , 2021, 40, 2529-2533.	2.2	5
68	Mavrilimumab for severe COVID-19 “ Authors' reply. <i>Lancet Rheumatology</i> , The, 2020, 2, e662-e663.	3.9	4
69	Letter by Campochiaro et al Regarding Article, “Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity” <i>Circulation</i> , 2018, 137, 2421-2422.	1.6	3
70	A3.21...MicroRNA-34a and microRNA-155 in Systemic Sclerosis: possible epigenetic biomarkers of endothelial dysfunction in VEDOSS and long-standing disease. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A50.1-A50.	0.9	3
71	Association of anti-RNA polymerase III antibody with silicone breast implants rupture in a multicentre series of Italian patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 25-28.	0.8	3
72	Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 179-188.	1.7	3

#	ARTICLE	IF	CITATIONS
73	Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis. Journal of Clinical Rheumatology, 2018, 25, 1.	0.9	2
74	AB0621â€¦GENDER DIFFERENCES IN CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASU ARTERITIS. , 2019, , .		2
75	A Novel Histiocytosis With Synovial and Skin Involvement. Annals of Internal Medicine, 2021, 174, 273-274.	3.9	2
76	Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: The Role of Endomyocardial Biopsy. Journal of Rheumatology, 2019, 46, 1421-1422.	2.0	1
77	Canakinumab injection for the treatment of active Stillâ€™s disease, including adult-onset Stillâ€™s disease. Expert Opinion on Orphan Drugs, 2021, 9, 77-86.	0.8	1
78	Cardiac immuneâ€¦related adverse events: anâ€™immuneâ€™cardioâ€™oncology puzzle. European Journal of Heart Failure, 2021, 23, 1748-1749.	7.1	1
79	Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis. Journal of Clinical Rheumatology, 2018, , 1.	0.9	1
80	Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. Clinical and Experimental Rheumatology, 0, , .	0.8	1
81	168.â€¦GENDER DIFFERENCES IN CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASUâ€™S ARTERITIS. Rheumatology, 2019, 58, .	1.9	0
82	Diagnostic approach and novel therapeutic option for cardiac inflammatory disorders. Comment on â€œAntisynthetase syndrome and cardiac involvement: a rare associationâ€•by Meudec et al. Joint Bone Spine 2018. doi: 10.1016/j.jbspin.2018.09.019. Joint Bone Spine, 2019, 86, 407.	1.6	0
83	THU0570â€¦EFFICACY AND SAFETY OF ANAKINRA IN THE TREATMENT OF AUTOIMMUNE MYOCARDITIS. , 2019, , .		0
84	FRI0302â€¦SAFETY AND EFFICACY OF RITUXIMAB BIOSIMILAR IN SYSTEMIC SCLEROSIS: AN ITALIAN MULTICENTER STUDY. , 2019, , .		0
85	Improvements of vascular outcomes in systemic sclerosis: halfway through, but still far to go. Rheumatology, 2022, , .	1.9	0
86	Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0